What happened with AMS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
American Shared Hospital Services operates centers where patients receive focused radiation treatments, including Gamma Knife radiosurgery and radiation therapy for cancer. Direct patient services provide the larger share of revenue. Its centers in Rhode Island, Peru, Ecuador and Mexico contract with individual patients and collect payment from patients, insurers or government payers.
Hospital equipment leasing supplies the rest of the business. The company provides Gamma Knife and proton beam therapy systems, and hospitals pay either a fee for each procedure or a share of treatment reimbursement. These contracts do not guarantee minimum payments, so owning and placing equipment does not by itself ensure income.
Revenue depends on treatment volume, physician referrals and reimbursement rates. Commercial insurers generally pay more than government programs, making the mix of payers important. Two customers together supply most of the company's revenue. Financing also constrains operations: loan agreements restrict borrowing, acquisitions and distributions. As of the latest annual report, Fifth Third had suspended further revolving-credit advances following covenant defaults, and the company was seeking a waiver and amendment.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
American Shared Hospital Services’ results hinge on treatment volumes, reimbursement, site contracts and continued financing, while Elekta and Varian also compete by selling radiation equipment directly to hospitals.
Accuray Incorporated competes for hospitals that could otherwise lease radiation-treatment equipment from American Shared Hospital Services, which earns fees per treatment or a share of hospital reimbursement rather than an upfront equipment sale. Watch Accuray’s hospital equipment sales and CyberKnife business: CyberKnife offers an alternative to the Gamma Knife treatments that generate AMS revenue.
Fed Interest Rate Decision
The Fed’s rate decision signals whether borrowing costs across the economy are rising or falling; because American Shared Hospital Services has floating-rate Fifth Third debt, that can change its interest expense and cash available while it works to address its debt and liquidity needs.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed’s rate is higher than expected, interest on the company’s floating-rate debt may rise, leaving less cash to meet debt payments and fund operations as it seeks an extension.
If it comes in below expectations
If the Fed’s rate is lower than expected, interest on the company’s floating-rate debt may ease, leaving more cash for debt payments and operations as it seeks an extension.
Accuray Incorporated earningsARAY
Accuray's report will show whether hospitals are buying its equipment and CyberKnife systems, an alternative competing for sites and treatment demand that American Shared Hospital Services serves with leased equipment.
Look at Accuray's hospital equipment sales and CyberKnife business together. Strength in both would show hospitals investing in systems that compete with options such as Gamma Knife, giving American Shared Hospital Services' leasing business and treatment demand a stronger substitute to contend with; weakness in both would point to less pressure from this competitive route, not prove stronger demand for the company's own equipment or services.
American Shared Hospital Services earningsThis company
American Shared Hospital Services' report will show whether revenue from treating patients can keep growing without treatment costs consuming more of it.
Read direct patient-service revenue alongside costs of revenue as a share of total revenue. Rising treatment revenue with a falling cost share would show that LINAC, Gamma Knife and PBRT services are growing with better cost coverage; flat revenue or a rising cost share would show that treatment volume and reimbursement are not yet covering the cost of delivering care well enough.
